{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,13]],"date-time":"2026-03-13T17:25:16Z","timestamp":1773422716237,"version":"3.50.1"},"reference-count":13,"publisher":"Wiley","issue":"8","license":[{"start":{"date-parts":[[2021,11,3]],"date-time":"2021-11-03T00:00:00Z","timestamp":1635897600000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/onlinelibrary.wiley.com\/termsAndConditions#vor"}],"content-domain":{"domain":["onlinelibrary.wiley.com"],"crossmark-restriction":true},"short-container-title":["Int J Dermatology"],"published-print":{"date-parts":[[2022,8]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:sec><jats:title>Background<\/jats:title><jats:p>The term super responders defines a subset of patients with moderate\u2010to\u2010severe psoriasis that present a rapid and higher rate of response to biological treatments in comparison to the general population. Little scientific evidence to explain the behavior and clinical characteristics of these psoriatic patients has been published thus far. Its characterization could be important to improve therapeutic optimization and to identify the profile of patients that will respond efficiently to biological treatments.<\/jats:p><\/jats:sec><jats:sec><jats:title>Objectives<\/jats:title><jats:p>The main objective of this study was to evaluate and characterize the proportion of super\u2010responder patients (who achieved PASI\u2009=\u20090 at week 12 and 24) in a total of 87 patients with moderate\u2010to\u2010severe psoriasis treated with guselkumab. Also, our intent was to analyze and evaluate differences in response to guselkumab in absolute PASI, PASI 75, PASI 90, PASI 100, BSA, VAS pruritus, and DLQI between groups.<\/jats:p><\/jats:sec><jats:sec><jats:title>Results<\/jats:title><jats:p>A total of 14 out of 87 patients treated with guselkumab were characterized as SR. No differences in demographic characteristics were found. The percentage of patients reaching PASI 75, PASI 90, and PASI 100 were numerically greater for SR than N\u2010SR at week 12, 24, 36, and 52. These differences were more pronounced for PASI 100 &gt; PASI 90 &gt; PASI 75. SR performed better and faster to guselkumab treatment as assessed by absolute PASI, BSA, VAS pruritus, and DLQI. Statistically significant differences were found in absolute PASI, BSA, VAS pruritus, and DLQI between groups along the 52\u2009weeks of study. No differences in drug survival were found between groups (<jats:italic>P<\/jats:italic>\u2009=\u20090.3326).<\/jats:p><\/jats:sec><jats:sec><jats:title>Conclusion<\/jats:title><jats:p>Our study demonstrated for the first time, in a real clinical practice setting, the presence of a subpopulation of patients that super respond to guselkumab at week 12 and 24 and maintain this efficacy for 52\u2009weeks. Further research must be performed to identify basal specific characteristics of this SR population.<\/jats:p><\/jats:sec>","DOI":"10.1111\/ijd.15784","type":"journal-article","created":{"date-parts":[[2021,11,3]],"date-time":"2021-11-03T18:15:29Z","timestamp":1635963329000},"page":"1029-1033","update-policy":"https:\/\/doi.org\/10.1002\/crossmark_policy","source":"Crossref","is-referenced-by-count":17,"title":["Super responders to guselkumab treatment in moderate\u2010to\u2010severe psoriasis: a real clinical practice pilot series"],"prefix":"10.1111","volume":"61","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-0381-6174","authenticated-orcid":false,"given":"Ricardo","family":"Ruiz\u2010Villaverde","sequence":"first","affiliation":[{"name":"Dermatology Department Hospital Universitario San Cecilio Granada Spain"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Lourdes","family":"Rodriguez\u2010Fernandez\u2010Freire","sequence":"additional","affiliation":[{"name":"Dermatology Department Hospital Universitario Virgen del Rocio Sevilla Spain"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jose C.","family":"Armario\u2010Hita","sequence":"additional","affiliation":[{"name":"Dermatology Department Hospital Universitario Puerto Real C\u00e1diz Spain"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Amalia","family":"P\u00e9rez\u2010Gil","sequence":"additional","affiliation":[{"name":"Dermatology Department Hospital Universitario Virgen de Valme Sevilla Spain"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Manuel","family":"Gal\u00e1n\u2010Guti\u00e9rrez","sequence":"additional","affiliation":[{"name":"Dermatology Department Hospital Universitario Reina Sof\u00eda C\u00f3rdoba Spain"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"311","published-online":{"date-parts":[[2021,11,3]]},"reference":[{"key":"e_1_2_8_2_1","doi-asserted-by":"publisher","DOI":"10.1046\/j.1365-2230.2001.00832.x"},{"key":"e_1_2_8_3_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(14)61909-7"},{"key":"e_1_2_8_4_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.ad.2013.12.008"},{"key":"e_1_2_8_5_1","unstructured":"European Medicine Agency.Tremfya \u2010 Summary of products and characteristics.2017;(February):2017. Available from:https:\/\/ec.europa.eu\/health\/documents\/community\u2010register\/2017\/20171110139063\/anx_139063_en.pdf."},{"key":"e_1_2_8_6_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaad.2016.11.041"},{"key":"e_1_2_8_7_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaad.2019.11.040"},{"key":"e_1_2_8_8_1","doi-asserted-by":"publisher","DOI":"10.1111\/bjd.15750"},{"key":"e_1_2_8_9_1","doi-asserted-by":"publisher","DOI":"10.1111\/jdv.15659"},{"key":"e_1_2_8_10_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jval.2019.04.116"},{"key":"e_1_2_8_11_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaad.2020.06.668"},{"key":"e_1_2_8_12_1","unstructured":"EUCTR2018\u2010001238\u201016\u2010FR. A study to evaluate further therapeutic strategies with guselkumab in patients with moderate\u2010to\u2010severe plaque\u2010type psoriasis.2019. Available from:https:\/\/www.cochranelibrary.com\/central\/doi\/10.1002\/central\/CN\u201002067950\/full;http:\/\/www.who.int\/trialsearch\/Trial2.aspx?TrialID=EUCTR2018\u2010001238\u201016\u2010FR."},{"key":"e_1_2_8_13_1","doi-asserted-by":"publisher","DOI":"10.1111\/dth.13344"},{"key":"e_1_2_8_14_1","doi-asserted-by":"publisher","DOI":"10.1111\/dth.14798"}],"container-title":["International Journal of Dermatology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1111\/ijd.15784","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/full-xml\/10.1111\/ijd.15784","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1111\/ijd.15784","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,4,15]],"date-time":"2024-04-15T08:16:29Z","timestamp":1713168989000},"score":1,"resource":{"primary":{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/10.1111\/ijd.15784"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,11,3]]},"references-count":13,"journal-issue":{"issue":"8","published-print":{"date-parts":[[2022,8]]}},"alternative-id":["10.1111\/ijd.15784"],"URL":"https:\/\/doi.org\/10.1111\/ijd.15784","archive":["Portico"],"relation":{},"ISSN":["0011-9059","1365-4632"],"issn-type":[{"value":"0011-9059","type":"print"},{"value":"1365-4632","type":"electronic"}],"subject":[],"published":{"date-parts":[[2021,11,3]]},"assertion":[{"value":"2021-03-18","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2021-06-18","order":1,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2021-11-03","order":2,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}